Intentar ORO - Gratis

FAKE DRUGS - BOOM PUMMELS PHARMA INDUSTRY

BioSpectrum Asia

|

BioSpectrum Asia May 2021

Fake pharmaceuticals are continuing to flood into clinics and hospitals across Asia despite monitored regulations in China and India, when suppliers crossing the border to less-regulated countries. Counterfeiters are moving across certain less regulated locations in Southeast Asia to sustain the trade. Pharmaceutical industry is committed and thriving to sustain and secure the legitimate supply chain. Given the complexity of the supply chain, this is an essential, but laborious effort that requires an efficient, multi-faceted strategy. A holistic approach comprising the use of concealed and unconcealed anti-counterfeiting features, a well-regulated, secure supply chain and appropriate laws and penalties to deter and punish counterfeiters is necessary to provide maximum patient protection.

- Hithaishi C Bhaskar

FAKE DRUGS - BOOM PUMMELS PHARMA INDUSTRY

As the COVID-19 pandemic continues to affect the world and with the global rush in the development and distribution of vaccines, criminal groups and unscrupulous enterprising people have also been active in counterfeiting COVID-19-related health products. The Philippines through the Philippine Center on Transnational Crime, INTERPOL National Central Bureau, Office of the President of The Philippines has received reports that South African authorities have seized hundreds of fake COVID-19 vaccines and Some 400 ampoules containing the fake vaccine were found at a warehouse in Germiston, Gauteng. Further investigation by the INTERPOL revealed the presence of organized crime networks targeting COVID-19 vaccines, both physically and online. Concerned pharmaceutical companies assisted in the identification of fake vials. Criminals have been put behind bars and investigations are continuing.

According to a FDA Advisory No. 20210664 by The Philippines authorities on Public Health Warning on Fake COVID-19 Vaccines, it noted that in February 2021, the World Health Organization (WHO) reported that a falsified COVID-19 vaccine in Mexico identified as “BNT162b2”, manufactured by Pfizer- BioNTech with lot number 783201. The falsified product was supplied and administered to patients outside authorized vaccination programs. The genuine manufacturer of COVID-19 Vaccine BNT162b2 confirmed they did not manufacture the product. Laboratory analysis of the contents of the falsified products is still pending as of today. Falsified COVID-19 vaccines pose a serious risk to global public health and place an additional burden on vulnerable populations and health systems.

MÁS HISTORIAS DE BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Collaborative R&D: Partnerships shaping the future of biopharma

Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.

time to read

2 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Quantum Computing: Future of diagnostics is being coded today

A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.

time to read

4 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

First Pacific woman to serve as public health director in NZ

The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Hugel launches botulinum toxin Letybo in Malaysia

South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Australia designs smart wound monitor to improve chronic infection care

Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Revvity unveils innovative reagent technology to accelerate therapeutics development

US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B

Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education

HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI

Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.

time to read

1 min

BioSpectrum Asia Sep 2025

Translate

Share

-
+

Change font size